Shota:
- MiNA to receive $25M as up front and is eligible to receive $245M as milestones for each of five potential targets along with royalties on product sales resulting from the collaboration
- Lilly will be responsible for the pre/ clinical development of candidates and will retain exclusive commercialization rights for any products emerges during the collaboration. The new technology will expand the breadth of Lilly’s RNA therapeutics platform
- The collaboration will deploy MiNA’s small activating RNA technology platform to research up to five targets selected by Lilly addressing its key therapeutic areas
Click here to read full press release/ article | Ref: PRNewswire | Image: Eli Lilly
The post Lilly Signs a ~$1.25B Research Collaboration with MiNA Therapeutics to Develop saRNA Therapies first appeared on PharmaShots.
